netFormulary Dorset NHS
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
Poole Hospital NHS Foundation Trust
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
 
 Search
 Formulary Chapter 9: Nutrition and blood - Full Chapter
Notes:

Chapter review date:

 Details...
09.01.03  Expand sub section  Drugs used in hypoplastic, haemolytic, and renal anaemias
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice
Amber SCG
In essential thrombocythaemia 
Antilymphocyte immunoglobulin
View adult BNF View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England in accordance with BCSH guidelines 
   
Eculizumab (Soliris®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
BlueTeq

Commissioned by NHS England for aHUS as per NHS England Policy E03/PS(HSS)/a: On recommendation from Newcastle specialist centre only.

Also commissioned by NHS England for paroxysmal nocturnal haemoglobinuria as per NHS National Specialised Commissioning Team (NSCT) Service Specification.

 
Link  NHS England Clinical Commissioning Policy Statement: E03/PS(HSS)/a Eculizumab for atypical haemolytic uraemic syndrome
   
Anti-Human Thrombocyte Globulin (horse) Inj 100 mg in 5mL
 Track Changes
Unlicensed Drug Unlicensed
Red
RBCH: Aplastic anaemia - See guidelines 
   
Oxymetholone
View adult BNF View childrens BNF  Track Changes
Unlicensed Drug Unlicensed
Red
Restricted Item RBCH only: Consultant Haematologist prescription 
   
09.01.03  Expand sub section  Erythropoietin
Recombinant human erythropoietins
(Non-renal indications)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Prescriber must specify which epoetin is required.


For use in patients in accordance with NICE TA323 or local commissioning statement for patients with symptomatic anaemia due to low-risk MDS.
Choice of agent dependent on Trust and procurement costs.

RBCH: Epoetin alfa (Eprex®) for Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy

RBCH: Epoetin alfa (Eprex®) 40,000 units for pre-operative anaemia prior to elective orthopaedic surgery (1 year funding from June 2014) 
Link  Commissioning statement for erythropoiesis stimulating agents
Link  Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (NICE TA323)
Link  Letter to professionals October 2017 - Recombinant human erythropoietins adverse reactions
Link  RBCH Pre-operative anaemia prior to elective orthopaedic surgery guideline
   
Recombinant human erythropoietins ((all variants))
(Renal anaemia)
View adult BNF View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England (for dialysis-induced anaemia only including via outpatients and only as per NICE CG114) and Trust Guidelines.

Use product with lowest procurement cost.

Prescriber must specify which epoetin is required.


DCHFT:
  • Darbopoetin (Aranesp®) First line. Home delivery only.

  • Epoetin beta (NeoRecormon®) Second line if patient allergic to or intolerant of darbopoetin.

  • Methoxy polyethylene glycol-epoetin beta (Mircera®) Second line if patient allergic to or intolerant of darbopoetin.
  •  
       
    Darbepoetin (Aranesp®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Red
    High Cost Medicine

    Commissioned by NHS England (for dialysis-induced anaemia including via outpatients and only as per NICE CG114) and Trust Guidelines.

     
    Link  Letter to professionals October 2017 - Recombinant human erythropoietins adverse reactions
    Link  NG8 - Anaemia management in chronic kidney disease (Previously -NICE CG114)
       
    Methoxy Polyethylene Glycol-Epoetin Beta (Mircera®)
    View adult BNF View childrens BNF  Track Changes
    Formulary
    Red
     
    Link  Letter to professionals October 2017 - Recombinant human erythropoietins adverse reactions
       
    09.01.03  Expand sub section  Iron overload
    Deferasirox (Exjade®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Red
    High Cost Medicine

    Commissioned by NHS England for iron chelation in thalassaemia and sickle cell - policy in progress.

     
       
    Deferiprone (Ferriprox®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Red
    High Cost Medicine
    Commissioned by NHS England for iron chelation in thalassaemia and sickle cell - policy in progress. 
       
    Desferrioxamine Mesilate
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Red
    High Cost Medicine
    Commissioned by NHS England for iron chelation in thalassaemia and sickle cell - policy in progress. 
       
     ....
     Non Formulary Items
    Epoetin Theta  (Eporatio®)

    View adult BNF View childrens BNF
    Non Formulary
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Green

    May be initiated, stabilised and maintained in primary, secondary or tertiary care  

    Amber

    Amber drug - without shared care  

    Amber SCG

    Amber drug - with shared care guideline  

    Red

    For secondary or tertiary care initiation and long-term maintenance of prescribing  

    Black

    Not recommended  

    netFormulary